华森制药
(002907)
| 流通市值：49.87亿 | | | 总市值：61.43亿 |
| 流通股本：3.39亿 | | | 总股本：4.18亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 413,550,709.65 | 211,846,896.79 | 827,144,563.24 | 625,912,023.87 |
| 营业总成本 | 349,874,529.4 | 177,299,368.93 | 767,774,090.85 | 557,825,404.58 |
| 其他经营收益 | | | | |
| 营业利润 | 68,011,473.8 | 37,639,523.2 | 93,963,234.13 | 105,996,120.47 |
| 利润总额 | 67,796,358.73 | 37,601,107.37 | 77,456,538.17 | 89,546,089.28 |
| 净利润 | 55,953,671.01 | 28,907,807.97 | 55,210,478.38 | 67,918,133.17 |
| 每股收益 | | | | |
| 其他综合收益 | -415,472.41 | -65,466.58 | -394,361.81 | -49,336.4 |
| 综合收益总额 | 55,538,198.6 | 28,842,341.39 | 54,816,116.57 | 67,868,796.77 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,173,710,864.78 | 1,158,496,630.86 | 1,128,841,585.98 | 1,089,026,686.7 |
| 非流动资产: | | | | |
| 非流动资产合计 | 875,683,578.3 | 876,618,124.26 | 898,316,934.73 | 908,674,080.35 |
| 资产总计 | 2,049,394,443.08 | 2,035,114,755.12 | 2,027,158,520.71 | 1,997,700,767.05 |
| 流动负债: | | | | |
| 流动负债合计 | 252,292,150.77 | 247,588,564.66 | 264,440,404.05 | 233,467,375.39 |
| 非流动负债: | | | | |
| 非流动负债合计 | 50,489,214.06 | 51,407,702.16 | 55,531,310.18 | 54,196,087.7 |
| 负债合计 | 302,781,364.83 | 298,996,266.82 | 319,971,714.23 | 287,663,463.09 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,737,778,465.02 | 1,724,379,055.36 | 1,691,321,668.84 | 1,688,745,803.43 |
| 股东权益合计 | 1,746,613,078.25 | 1,736,118,488.3 | 1,707,186,806.48 | 1,710,037,303.96 |
| 负债和股东权益合计 | 2,049,394,443.08 | 2,035,114,755.12 | 2,027,158,520.71 | 1,997,700,767.05 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 430,488,843.83 | 200,037,203.77 | 839,947,707.16 | 638,169,723.83 |
| 经营活动现金流出小计 | 375,827,300.56 | 175,560,654.25 | 777,707,884.69 | 613,377,303.96 |
| 经营活动产生的现金流量净额 | 54,661,543.27 | 24,476,549.52 | 62,239,822.47 | 24,792,419.87 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 353,864,174.05 | 202,053,938.73 | 661,941,316.73 | 561,849,047.49 |
| 投资活动现金流出小计 | 366,415,202.69 | 204,445,808.87 | 866,557,492.36 | 698,444,809.22 |
| 投资活动产生的现金流量净额 | -12,551,028.64 | -2,391,870.14 | -204,616,175.63 | -136,595,761.73 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | - |
| 筹资活动现金流出小计 | 17,156,749.66 | 240,848.55 | 39,742,990.04 | 41,600,936.87 |
| 筹资活动产生的现金流量净额 | -17,156,749.66 | -240,848.55 | -39,742,990.04 | -41,600,936.87 |
| 汇率变动对现金及现金等价物的影响 | -129,485.5 | -65,485.02 | -95,317.35 | -179,691.37 |
| 现金及现金等价物净增加额 | 24,824,279.47 | 21,778,345.81 | -182,214,660.55 | -153,583,970.1 |
| 期末现金及现金等价物余额 | 299,161,514.32 | 296,115,580.66 | 274,337,234.85 | 302,967,925.3 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 24,824,279.47 | - | -182,214,660.55 | - |